FP
HZNP

Foundry Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Foundry Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-30,486
Closed -$2.23M – 458
2020
Q4 		$2.23M Sell
30,486
-25,048
-45% -$1.86M 0.09% 269
2020
Q3 		$4.31M Sell
55,534
-15,036
-21% -$1.03M 0.21% 145
2020
Q2 		$3.92M Sell
70,570
-2,706
-4% -$116K 0.19% 156
2020
Q1 		$2.17M Sell
73,276
-13,039
-15% -$441K 0.12% 204
2019
Q4 		$3.13M Sell
86,315
-33,148
-28% -$1.02M 0.12% 224
2019
Q3 		$3.25M Sell
119,463
-280
-0.2% -$7.24K 0.13% 217
2019
Q2 		$2.88M Sell
119,743
-352
-0.3% -$8.93K 0.11% 225
2019
Q1 		$3.17M Sell
120,095
-7,746
-6% -$184K 0.13% 222
2018
Q4 		$2.5M Buy
127,841
+18,111
+17% +$355K 0.11% 249
2018
Q3 		$2.15M Sell
109,730
-171
-0.2% -$3.25K 0.08% 278
2018
Q2 		$1.82M Sell
109,901
-6,950
-6% -$106K 0.07% 288
2018
Q1 		$1.66M Buy
+116,851
New +$1.73M 0.07% 294

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Foundry Partners's HZNP Position: Q1 2021 in Review

Foundry Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2021, closing a stake of 30,486 shares — an estimated $2.23M sold.

Foundry Partners first reported a position in HZNP in Q1 2018 and held it in 12 quarters. The position peaked at $4.31M in Q3 2020. 516 funds tracked by Wall St. Rank hold HZNP as of Q1 2021.

  • Foundry Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2021 after selling out during the quarter.
  • Foundry Partners sold 30,486 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2021, an estimated $2.23M.
  • Foundry Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2018 and held it in 12 quarters.
  • Foundry Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.31M in Q3 2020.
  • 516 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2021.

Based on Foundry Partners's 13F filing for Q1 2021, filed 12 May 2021.